Initial Evaluation and Testing for Suspected Connective Tissue Disorder

Essential First-Line Laboratory Tests

The American College of Rheumatology recommends a structured approach beginning with screening autoantibodies and baseline inflammatory assessment, including ANA, rheumatoid factor, complete blood count with differential, inflammatory markers, comprehensive metabolic panel, and hepatitis B, C, and HIV serologies as the initial laboratory panel 1
ANA is the essential screening test, positive in 10-20% of patients with interstitial lung disease and up to 40% of patients with idiopathic pulmonary arterial hypertension 1
Rheumatoid factor has 70% specificity with moderate sensitivity for rheumatoid arthritis, though 15% of first-degree relatives of RA patients may have positive RF 1, 2
CRP is preferred over ESR as it is more reliable, not age-dependent, and provides a simple, validated, reproducible test 1, 2
Complete blood count with differential detects cytopenias, anemia, or abnormal cell populations indicating systemic inflammation or autoimmune disease 1
Comprehensive metabolic panel including liver function tests, renal function, glucose, and urate levels for baseline assessment 1, 2
Hepatitis B, C, and HIV serologies are required to exclude these as associated diagnoses or confounding factors, and are mandatory before initiating any DMARD therapy 1, 2

Musculoskeletal manifestations, such as joint pains, musculoskeletal pain, weakness, morning stiffness duration, and difficulty making a fist, should be assessed 1, 2
Systemic symptoms, including fatigue, fever, and weight loss, should be evaluated 1
Vascular phenomena, such as Raynaud's phenomenon and photosensitivity, should be assessed 1
Serosal involvement, including pleuritis and pericarditis, should be evaluated 1
Sicca symptoms, including dry eyes and dry mouth, should be assessed 1
Skin findings, such as psoriatic plaques, nail changes, sclerodactyly, digital tip ulcers, and telangiectasia, should be examined 1, 2

For systemic sclerosis, anti-centromere, anti-topoisomerase-1, and anti-U3RNP antibodies should be tested when skin findings or Raynaud's phenomenon are present 1
For Sjögren's syndrome, anti-SSA/Ro and anti-SSB/La antibodies should be tested 1
For inflammatory myopathies, anti-synthetase antibodies and creatine kinase should be tested when muscle weakness and elevated CK are present 1
For rheumatoid arthritis, anti-citrullinated protein antibodies with 90% specificity and 60% sensitivity should be tested 1, 2
For vasculitis, antineutrophil cytoplasmic antibodies should be tested if vasculitis is suspected 1

High-resolution CT of the chest is the gold standard for diagnosing interstitial lung disease and should be performed even in asymptomatic patients with systemic sclerosis 1
Pulmonary function tests, including FVC and DLCO, should be obtained at baseline for all patients and repeated every 6 months for patients with ILD risk 1
Baseline X-rays of hands, wrists, and feet bilaterally should be taken to assess for erosions, which predict persistent inflammatory disease and aggressive disease 1, 2

Connective tissue disorder should not be dismissed based on normal CRP/ESR alone, as approximately 20% of patients with active connective tissue disease may have normal inflammatory markers 1
Diagnostic workup should not be delayed, and additional testing should be tailored to the clinical presentation 1
Extensive coronary calcification should not be ordered when evaluating for connective tissue disease, as this is not recommended for identifying individuals with obstructive CAD 3

The American College of Rheumatology recommends establishing multidisciplinary collaboration integrating rheumatology, pulmonology, and radiology expertise for optimal diagnosis and management 1

Pulmonary function tests should be performed every 6 months for the first 3-4 years after diagnosis 1
Annual HRCT should be performed for the first 3-4 years after diagnosis 1
Inflammatory markers, including CRP and ESR, should be repeated at each visit to monitor disease activity 1, 2